Loading...
•
Dec 31, 2021
Biogen Q4 2021 Earnings Report
Biogen's Q4 2021 performance reflected resilience amidst challenges, marked by key strategic developments and financial results.
Key Takeaways
Biogen reported a Q4 2021 revenue of $2,734 million, a 4% decrease compared to the prior year. GAAP diluted EPS was $2.50, while Non-GAAP diluted EPS reached $3.39. The company is actively engaging with the Centers for Medicare and Medicaid Services on ADUHELM reimbursement and progressing its pipeline with key data readouts and regulatory filings expected in 2022.
Total revenue for the fourth quarter was $2,734 million, down 4% year-over-year.
GAAP diluted EPS for the fourth quarter was $2.50, and Non-GAAP diluted EPS was $3.39.
Biogen is selling its equity in its biosimilar joint venture to Samsung Biologics for up to $2.3 billion.
The company is progressing its pipeline with 5 key data readouts and 3 regulatory filings expected in 2022.
Biogen
Biogen
Biogen Revenue by Segment
Biogen Revenue by Geographic Location
Revenue by Segment
Multiple Sclerosis Revenue
CapyFin.comRare Disease Revenue
CapyFin.comBiosimilars Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Biogen expects full year 2022 revenue to be between $9.7 billion and $10.0 billion, with Non-GAAP diluted EPS between $14.25 and $16.00. This guidance assumes minimal ADUHELM revenue and continued declines in RITUXAN and TECFIDERA revenue.
Positive Outlook
- Anticipated cost-reduction measures are estimated to yield approximately $500 million in annualized savings, with approximately $350 million expected to be realized in 2022.
- The company expects to utilize a portion of the remaining share repurchase authorization of $2.8 billion through the end of 2022.
- Non-GAAP R&D expense is expected to be between $2.2 billion and $2.3 billion.
- Non-GAAP SG&A expense is expected to be between $2.5 billion and $2.6 billion, including approximately $400 million in support of the launch of ADUHELM.
- The Non-GAAP tax rate for 2022 is expected to be between 15.5% and 16.5%.
Challenges Ahead
- Financial guidance assumes minimal ADUHELM revenue in 2022.
- Guidance assumes continued declines in RITUXAN revenue due to biosimilar competition.
- Guidance assumes continued erosion of TECFIDERA revenue in the U.S. due to generic entry and potential entry of TECFIDERA generics in the E.U.
- Decreased revenue from high margin products is expected to reduce gross margin percentage compared to 2021.
- The final National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease is currently uncertain and may impact anticipated results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income